Understanding Anemia in Patients with CKD: From Diagnosis to Data on Emerging AgentsPremiere Date: Wednesday, January 26, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, January 26, 2023
Note: Credit Is No Longer Available
|Pablo Pergola, MD, PhD (Moderator)
Renal Associates PA
San Antonio, TX
|Daniel W. Coyne, MD
Professor of Medicine
Director, Chromalloy American Kidney Center
Division of Nephrology
Washington University School of Medicine
St. Louis, MO
|Bruce S. Spinowitz, MD
Associate Director, Nephrology
Vice Chairman, Medicine
New York-Presbyterian Queens
Professor of Clinical Medicine
Weill Medical College of Cornell University
New York, NY
Anemia is a common complication of chronic kidney disease (CKD), and its prevalence increases with CKD stage. As it is associated with greater mortality, hospitalization, major adverse cardiovascular events (MACE),and CKD progression, the treatment of anemia and the restoration of optimal hemoglobin (Hb) values is critical among patients with dialysis-dependent (DD) and non-dialysis-dependent (NDD) CKD. Currently, conventional therapies for anemia in patients with CKD are limited, but the emergence of novel hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) may soon give clinicians new treatment options.
In this CME Outfitters interactive webcast, two experts in CKD will discuss the pathophysiology and signs and symptoms of anemia in patients with CKD, review current best practices for managing anemia in CKD, and explore the safety and efficacy of emerging HIF-PHIs.
At the end of this CE activity, participants should be able to:
- Review pathophysiology and signs and symptoms of anemia in patients with CKD.
- Implement evidence-based recommendations for the use of iron supplementation and ESAs for anemia in patients with CKD.
- Appraise the safety and efficacy, as well as pharmacokinetic (PK) and pharmacodynamic (PD) profiles, of emerging HIF-PHIs for CKD.
Supported by an educational grant from Akebia Therapeutics, Inc. and Otsuka America Pharmaceutical, Inc.
Nephrologists, primary care physicians, PAs, nurse practitioners, and pharmacists
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Dr Pergola reports the following financial relationships:
Consultant: Akebia Therapeutics; AstraZeneca; FibroGen, Inc.; and GlaxoSmithKline
Research Support: AstraZeneca
Dr Coyne reports the following financial relationships:
Consultant: AstraZeneca; FibroGen, Inc.; GlaxoSmithKline; and Otsuka Pharmaceutical Co., Ltd
Research Support: (All payments made to Washington University of Medicine) AstraZeneca and GlaxoSmithKline.
Dr Spinowitz reports the following financial relationships:
Consultant: AstraZeneca and Otsuka Pharmaceutical Co., Ltd.
Speakers Bureau: AstraZeneca; Bayer; and Fresenius Medical Care
Warren Beckman (planning committee) has no disclosures to report.
Kathleen Blake, PhD (planning committee) has no disclosures to report.
Susan H Yarbrough, CHCP (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).